INTRODUCTION 23
The progesterone receptor (PR), also known as NR3C3, plays a crucial role in the coordination of 24 several aspects of female reproductive development and function (1) 
40
Several experiments have revealed a tight association between the turnover rate of several NR and 41 their transcriptional activity, showing that both aspects of NR function appear to be inversely related 42 (13) (14) (15) (16) (17) (18) . Among the factors regulating PR levels are its ligands. It was initially shown that 43 administration of progesterone to ovariectomized guinea pigs provoked a rapid fall in uterine receptor 44 concentration (19) . Hormone-dependent down-regulation of PR has been finally confirmed by several 45 groups (20) (21) (22) but its biological significance is still unclear. Phosphorylation of PR on a key serine 46 residue (Ser294) by MAPKs was shown to couple multiple receptor functions, including ligand-47 dependent PR down-regulation by the ubiquitin-proteasome pathway (13). The concept that 48 transcriptional activation and ubiquitin-mediated proteolysis are interdependent processes is emerging 49 as a potentially important control mechanism of transcription (16, 23) . Although their significance remains to be defined, it appears that complex interactions between regulatory molecules governing 51 both transcription and ubiquitination/degradation exist (24-26). However, little is known concerning 52 the fate of coregulators during ligand-dependent NR down-regulation (27, 28) .
53
In a previous study, we have shown that SRC-1 is exported from the nucleus to the cytoplasm and 54 speculated that this export might be a regulatory mechanism controlling the termination of hormone 55 action possibly through its degradation (29) . In order to establish a link between SRC-1 proteolysis 56 and the PR-mediated transcription process, we studied the mechanism governing SRC-1 proteolysis at 57 the steady-state level and questioned whether the ligand could modulate its turn-over. In this study, we 58 demonstrate that SRC-1 undergoes covalent modifications by ubiquitin which targets the coactivator 59 to the proteasome at the steady-state level. We identify two critical degron domains directly linked to 60 the coactivator proteolysis. Aside from this ligand-independent stability regulation, we show that 61 SRC-1 undergoes accelerated agonist-dependent and PR-mediated down-regulation via the ubiquitin-62 proteasome pathway. SRC-1 proteolysis occurs concomitantly of ligand-dependent PR degradation. Of 63 note, the nature of the ligand is shown to be critical for this process since both PR and SRC-1 ligand-64 dependent proteolysis was inhibited in the presence of RU486, leading to dramatic loss of PR
RESULTS

68
SRC-1 mainly colocalizes with cytoplasmic proteasome antigens
69
In our previous report about the regulatory mechanisms of SRC-1 subcellular trafficking, we have 70 shown that SRC-1 localizes both in nuclear and cytoplasmic corpuscular structures (29) . Several 71 studies have reported coregulators localization in organelles (30, 31) . We tried to identify the nature of 72 these cytoplasmic and nuclear speckles by colocalization studies with various antigens and with 73 fluorescent organelles markers. Since several nuclear receptors (NR) and coactivators such as SRC- 3 74 have been shown to interact with the proteasome (32, 33), we used confocal microscopy to investigate 75 whether proteasome components might also accumulate in SRC-1 speckles. By using antibodies 76 directed against the human S7 subunit of the 19S (Rpt1) and the α/β subunits of the 20S proteasome,
77
we found that SRC-1 colocalized with both 26S proteasome antigens ( Fig 1A and Supplemental Fig   78   S1 ). The fluorescence intensity profile indicates that colocalization was predominant in SRC-1 79 speckles: simultaneous fluorescence intensity increase was observed in cytoplasmic speckles but also 80 in lesser extent in nuclear speckles (Fig 1B) , suggesting that SRC-1 is mainly but not exclusively 
90
SRC-1 is ubiquitinylated in vivo and is degraded by the proteasome
91
We next studied the mechanism of SRC-1 down-regulation. First we investigated whether the 92 coactivator was ubiquitinylated and targeted to the proteasome. COS-7 cells were transfected with the 93 expression vector encoding the full-length SRC-1 and incubated in the presence of proteasome 94 inhibitors, MG132 or epoxomicin. Consistent with previous reports (14, 35), both inhibitors increased 7 SRC-1 protein level in comparison to cells treated with vehicule (Fig 2A and Supplemental Fig S3) .
96
To demonstrate that SRC-1 is poly-ubiquitinylated, COS-7 cells were transfected with SRC-1 97 expression vector in the presence or absence of a vector encoding His-tagged ubiquitin (His 6-Ub) and 98 analyzed by Western Blot. In the absence of His 6-Ub, the anti-SRC-1 antibody detected a major band 99 of ~160 kDa (Fig 2B, left panel, lane 1) . In cells cotransfected with His 6-Ub expression vector, a 100 moderate decrease in band intensity was observed with a slightly higher molecular weight smear, 101 indicative of ubiquitinylated moieties (Fig 2B, left 
128
immunocytochemical studies (Fig 3A) and Western Blot experiments (Supplemental Fig S5) RT-PCR excluded the possibility of any ligand-dependent down-regulation of SRC-1 mRNA levels 137 (Supplemental Fig S6) . MG132 exposure inhibited the agonist-dependent proteolysis of SRC-1 (Fig   138   3B , lane 4), indicating that this stimulated down-regulation is mediated by the proteasome.
139
Importantly, using antibodies specifically detecting endogenous SRC-1, we similarly observed 140 agonist-dependent degradation of endogenous SRC-1 in Ishi-PR-B cells (Fig 3C and Fig 3D) . Of note, (Fig 3E) . Finally, we determined whether other p160 coactivators such 149 as SRC-2/TIF2/GRIP-1 or SRC-3/AIB1, which are also known proteasome targets (14), could be 150 degraded in response to R5020. None of these coactivators was significantly degraded under similar 151 experimental conditions (Supplemental Fig S7) , suggesting a target-specific coactivator effect of PR.
It has been initially proposed that antiprogestins are capable of inducing PR down-regulation but with 153 much slower kinetics than agonists (22). We therefore tried a longer time point to check if SRC-1 154 degradation was occurring in presence of RU486. The result shows that, in contrast to 24 h incubation
155
( Fig 3F, lane 3) , 48 h treatment with RU486 induced a significant reduction of both SRC-1 and PR
156
( Fig 3F, lane 4) . More importantly, in presence MG132, RU486 treatment resulted in a dramatic 157 accumulation of PR and SRC-1 (Fig 3F, lane 5 
180
To confirm that these motifs were involved in proteasome-mediated SRC-1 degradation, we compared 181 both mutants and wt SRC-1 localization by immunocytochemistry and found that in contrast to the 182 wild-type coactivator (Fig 1) and the ∆(PEST) mutant, the ∆(bHLH) mutant localized predominantly 183 in the nucleus (Fig 4C) . In contrast to the wild-type coactivator (Fig 1) , colocalization studies of both 184 mutants with 19S proteasome antigens S7/Rpt1 and with the α/β proteasome 20S subunits showed no 185 significant overlap (Fig 4C and data not 
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Since we showed that SRC-1 could be partially proteolyzed in the cytoplasm where it colocalized in 213 speckles with the proteasome (Fig 1) , we next wondered if PR will colocalize in the same cytoplasmic 
278
We have previously shown that SRC-1 is a transcriptional coactivator whose localization is 279 hormonally regulated in the presence of PR (29). Mainly functioning in the nuclear compartment, this 280 coactivator may also be present in the cytoplasm, predominantly concentrated in cytoplasmic speckles 281 (29) . Several studies have also demonstrated that p160 coregulators might be localized in the 282 cytoplasm (7, 30, 31) . Although the concentration of SRC-1 in cytoplasmic speckles was initially 283 reported to be linked to overexpression (49), it has been also observed for endogenous p160 284 coactivators (50) and, more importantly, a recent study correlated this archetypical distribution with 285 the cytoplasmic sequestration of SRC-1 by SIP (SRC-Interacting Protein) (51). During our primary search to identify the nature of these speckles, we initially observed a colocalization between SRC-1 287 and proteasome antigens, indicating that SRC-1 cytoplasmic speckles are enriched of proteasome 288 components ( Fig 1A) . Similar subcellular distribution studies already reported SRC-2 colocalization 289 with proteasome antigens but specifically at the nuclear level (34, 52) . Coactivator/proteasome 290 interaction have been also described at the biochemical level for the p160 coactivators (33, 53), as well 291 as NR such as the thyroid receptor, the retinoic acid receptors RARα and RXR, the estrogen receptor 292 ERα, or the vitamin D receptor (32). We detected a strong colocalization in the cytoplasmic 293 compartment although a weaker colocalization in speckles was also observed in the nuclear 294 compartment (Fig 1B) indicative of a predominant but not exclusive proteolysis of the coactivator in 295 the cytoplasmic compartment. Interestingly, nuclear export of SRC-3 has been shown to be required 296 for its proteasomal degradation (54). However, our finding is not consistent with the work of Li et al.
297
who recently showed that proteasome-dependent turnover of SRC-3 occurs specifically in the nucleus 298 (39). Although we could not completely exclude that nuclear degradation also occurs for SRC-1 (see 299 colocalization profiles Fig 1B) , this discrepancy between SRC-1 and SRC-3 argues for the fact that 300 each SRC family member has different and specific physiological functions (55).
301
We have shown that the ubiquitin-proteasome pathway mediates selective degradation of SRC-1 and 
337
In spite of this, it is difficult to conceive how a coactivator will be paradoxically part of a coactivating 
MATERIALS AND METHODS
385
Hormone and inhibitors Gold mounting medium (Invitrogen, Carlsbad, CA). For standard microscopy (Fig 2 and 3 (Fig 1 and 4) , line scans of intensity profiles across the cells were generated Total RNA were extracted as described by the manufacturer. One microgram of each sample was 495 treated by DNase I and was reverse transcribed using random primers as previously described (77).
496
Real-time quantitative PCR of amphiregulin gene was performed as described (46) 
